<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712309</url>
  </required_header>
  <id_info>
    <org_study_id>ETAP Protocol 2.0</org_study_id>
    <nct_id>NCT00712309</nct_id>
  </id_info>
  <brief_title>Endovascular Treatment of Popliteal Artery - Balloon Angioplasty Versus Primary Stenting</brief_title>
  <acronym>ETAP</acronym>
  <official_title>Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions - Balloon Angioplasty Versus Primary Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herz-Zentrums Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herz-Zentrums Bad Krozingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Does primary stenting have a lower 12-month restenosis rate than PTA alone in the
           treatment of atherosclerotic lesions of the popliteal artery?

             -  Alternative hypothesis: &quot;Primary stenting with the Edwards LifeStent is associated
                with a lower restenosis rate than PTA alone in patients with atherosclerotic
                lesions of the popliteal artery at 12 months&quot;

             -  Null hypothesis: &quot;Primary stenting with the Edwards LifeStent is not associated
                with a lower 12-month restenosis rate than PTA alone in patients with
                atherosclerotic lesions of the popliteal artery&quot;&quot;

        2. Does comparison of the two intervention groups (PTA alone, stenting) disclose
           differences in terms of the secondary endpoints?

        3. How do the intervention methods compare in terms of safety/incidence of adverse effects?

        4. What are the long-term clinical implications of the two treatment methods?
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis rate (duplex ultrasound or angiographic stenosis &gt;50% of vascular lumen diameter; PVR &gt; 2.4 m/s)</measure>
    <time_frame>12-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Popliteal Artery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous transluminal angioplasty (PTA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lifestent</intervention_name>
    <description>Stent for endovascular treatment of popliteal artery lesions</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon-angioplasty (PTA)</intervention_name>
    <description>PTA for endovascular treatment of popliteal artery lesions</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is at least 21 years old

          -  The patient or legal representative provided written informed consent

          -  The patient agrees to comply with the protocol-mandated follow-up visits and testing
             regime

          -  The patient has lifestyle-limiting claudication or critical limb ischemia defined as:
             Fontaine stage IIa-IV/ Rutherford 1-5 category

          -  The target lesion located within the popliteal artery has angiographic evidence of
             stenosis &gt; 70% or occlusion (by visual estimate)

          -  At least one vessel runoff to the foot

          -  The patient has no other relevant inflow or outflow stenosis (&gt; 50%), however when
             needed iliac or femoral intervention may be done during study procedure.

        Exclusion Criteria:

          -  The patient is currently participating in a drug or another device study.

          -  The popliteal artery target lesion has previously been subintimal recanalized

          -  The patient has a history of bleeding diatheses or coagulopathy

          -  Female patients that are pregnant

          -  The patient has a contraindication (including allergic reaction) to platelet
             aggregation inhibitors or heparin

          -  The patient is unable to conform to the study protocol follow-up procedures or visits.

          -  The patient has a life expectancy of &lt;24 months

          -  The patient has concomitant renal failure which requires dialysis

          -  The patient has a contraindication (including allergic reaction) to or a known
             sensitivity to contrast media

          -  The duplex ultrasound/angiography of the target lesion must NOT meet the following
             criteria:

               -  The popliteal artery target lesion stenosis/occlusion is also continuously
                  located within the superficial femoral artery and/or tibiofibular tract

               -  The popliteal artery target lesion is restenotic

               -  The popliteal artery has been subintimal recanalized
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Zeller, MD</last_name>
    <phone>004976334024350</phone>
    <email>thomas.zeller@herzzentrum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aljoscha Rastan, MD</last_name>
    <phone>004976334024350</phone>
    <email>aljoscha.rastan@herzzentrum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD</last_name>
      <phone>004976334024350</phone>
      <email>thomas.zeller@herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Krankenberg, MD</last_name>
      <phone>0049408890090</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>February 9, 2009</last_update_submitted>
  <last_update_submitted_qc>February 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Thomas Zeller, MD</name_title>
    <organization>Herzzentrums Bad Krozingen</organization>
  </responsible_party>
  <keyword>atherosclerotic</keyword>
  <keyword>lesions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

